Clinical Trial

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Study acronym: NeckTAR-IN
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-10; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2025-11-27
Trial Details
NCT Number NCT07178847
Lead Sponsor Centre Jean Perrin
Conditions Locally Advanced Head and Neck Carcinoma
Enrollment 59 participants
Start Date 2025-10-13
Primary Completion 2029-04 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-13